BACKGROUND: Activated fibroblasts (myofibroblasts) play a critical role in cardiac fibrosis; however, their origin in the diseased heart remains unclear, warranting further investigation. Recent studies suggest the contribution of bone marrow fibroblast progenitor cells (BM-FPCs) in pressure overload-induced cardiac fibrosis. We have previously shown that interleukin-10 (IL10) suppresses pressure overload-induced cardiac fibrosis; however, the role of IL10 in inhibition of BM-FPC-mediated cardiac fibrosis is not known. We hypothesized that IL10 inhibits pressure overload-induced homing of BM-FPCs to the heart and their transdifferentiation to myofibroblasts and thus attenuates cardiac fibrosis.
H
eart failure is the leading cause of morbidity and mortality in the developing world. 1 A key component of heart failure is excessive extracellular matrix deposition by activated fibroblasts (myofibroblasts); this leads to cardiac fibrosis and pathological remodeling in myocardium. [2] [3] [4] Myofibroblasts play a prominent role in fibrotic processes and display unique biological functions, including increased production of fibrillar type I and III collagen. 3, [5] [6] [7] Myofibroblasts also express high levels of the contractile protein α-smooth muscle actin (αSMA), by which they can exert strong contraction forces, thereby reducing the damaged area. 5, 8, 9 In contrast, dysregulated activation of cardiac fibroblasts and their secreted cytokines and growth factors such as transforming growth factor-β (TGFβ) and endothelin enhances hypertrophic cardiac remodeling and ultimately leads to heart failure. In general, healthy myocardium does not contain myofibroblasts. The origin of the myofibroblasts responsible for the excessive collagen and other extracellular matrix protein production in a pressure overload-induced hypertrophic model has not been entirely elucidated. During development, cardiac fibroblast originates from mesenchymal cells derived primarily from the embryonic epicardium. 10, 11 It was previously thought that this source of mesenchymal cells does not persist into adulthood. 12, 13 However, mesenchymal stem cells have been found to significantly contribute to the wound healing process after myocardial infarction. 14 Previous studies have shown that myofibroblasts may originate from several sources, including expansion of resident fibroblasts, hematopoietic cells mobilized from bone marrow, 12, [15] [16] [17] or endothelial cells by the process of endothelial to mesenchymal transition. 18, 19 Recent studies suggest that a subpopulation of heart-infiltrating bone marrow (BM)-derived CD45 + cells expressing prominin 1 and other stem cell markers (such as cKit and Sca1) contributes to myofibroblast differentiation under the influence of the profibrotic factor TGFβ. 15, 20, 21 However, although it is now more widely accepted that there are other sources of myofibroblasts beyond resident cardiac fibroblasts, there is still debate about the extent to which these extracardiac cells contribute to cardiac fibrosis, thus indicating the need for further investigation. [22] [23] [24] MicroRNAs (miRNAs) are noncoding single-stranded RNAs (≈18-24 nucleotides in length) and are involved in posttranscriptional control of genes. Recently, they have emerged both as key regulators of cardiovascular disease and as potential drug targets. 25, 26 Emerging evidence suggests a pivotal role for miRNAs in cardiac fibroblast proliferation and differentiation. 26, 27 It has been demonstrated that TGFβ-Smad signaling plays a critical role in the regulation of miRNA-21 biogenesis in vascular smooth muscle cells. 28, 29 Furthermore, in vivo silencing of miRNA-21 suppresses TGFβ-induced noncanonical (extracellular signal-regulated kinase-mitogenactivated protein kinase) fibrotic signaling and prevents cardiac dysfunction in mice after transverse aortic constriction (TAC). 30 miRNA-21 regulates fibroblast survival and growth factor secretion, which ultimately control the extent of cardiac fibrosis and hypertrophy. 30, 31 However, the role of miRNA-21 in BM fibroblast progenitor cell (BM-FPC) transdifferentiation and in BM-FPC-mediated fibrosis has never been studied.
Interleukin-10 (IL10) is a pleiotropic cytokine that regulates the infiltration of monocytes/macrophages to the injured site and controls the synthesis of various proinflammatory cytokines and chemokines.
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Clinical Perspective
What Is New?
• Despite significant progress made in identifying molecular mechanisms that contribute to cardiac fibrosis over the past decades, its mechanistic basis is still not well understood.
• This study demonstrates that in addition to resident cardiac fibroblasts, bone marrow-derived myofibroblasts significantly contribute to progression of pathological cardiac fibrosis and that pleotropic anti-inflammatory cytokine interleukin-10 inhibits the recruitment and transdifferentiation of bone marrow fibroblast progenitor cells into the pressure-overloaded myocardium.
• At the molecular level, we show that interleukin-10 noticeably inhibits transforming growth factor-β-Smad2/3 signaling in activated bone marrow fibroblast progenitor cells.
• We discover that inhibition of transforming growth factor-β-Smad2/3 signaling mediated miRNA-21 maturation as a novel mechanism by which interleukin-10 inhibits bone marrow fibroblast progenitor cell-mediated cardiac fibrosis in the pressure-overloaded myocardium.
What Are the Clinical Implications?
• Left ventricular hypertrophy accompanied by myocardial fibrosis contributes to heart failure, but no medical therapies are particularly effective for retarding or reversing this maladaptive process.
• The results presented in this study have important clinical implications because bone marrow cells are involved in cardiac fibrosis only during pathological stress.
• Thus, selective inhibition of their homing to the heart and of fibrotic signaling using interleukin-10 or selective microRNAs might inhibit transition of physiological hypertrophy to heart failure and may be a potential therapeutic strategy to treat or prevent the development of hypertrophic remodeling in patients with heart failure.
IL10 therapy has been successfully tried in a variety of inflammatory diseases, including myocardial infarction and ischemic injury. 33, 34 Recently, we have shown that recombinant mouse lL10 treatment significantly inhibits local cytokine expression and subsequently attenuates pressure overload-induced inflammation and hypertrophic remodeling. 32 In fact, IL10 knockout (IL10KO) mice showed exaggerated fibrosis and IL10 treatment resulting in attenuated left ventricular fibrosis in multiple heart failure models (aortic banding, isoproterenol, angiotensin II, and myocardial infarction). 32, 34, 35 However, the molecular mechanisms for the antifibrotic effect of IL10 are not known. We and others have shown that IL10 regulates trafficking of BM stem/progenitor cells to the heart; however, the role of IL10 in homing of BM-FPCs to the heart and the contribution of IL10 to pathological fibrosis have never been studied. 34,35a In this study, we tested the hypothesis that IL10 inhibits BM-derived myofibroblast-mediated cardiac fibrosis and improves cardiac function in the pressureoverloaded myocardium. We report that TAC-induced mobilization and homing of BM-FPCs to the heart is augmented in IL10KO mice. Wild-type (WT) BM cell transplantation into IL10KO mice markedly reduced mobilization of BM-FPCs and reduced TAC-induced cardiac fibrosis. Furthermore, IL10 suppressed TGFβ-Smad signaling-induced miRNA-21 expression. The regulation of miRNA-21 expression by IL10 in activated BMFPCs could be a potential mechanism by which IL10 reduces fibrosis in the pressure-overloaded myocardium.
METHODS
Antibodies and Reagents
Antibodies against αSMA, collagen 1α, or FSP1 (fibroblastspecific protein 1) were purchased from Abcam, Inc (San Francisco, CA). Antibodies specific for pSmad2/3, total Smad, or GAPDH were purchased from Cell Signaling Technology, Inc (Boston, MA). For cell purification, prominin 1 and CD45 antibodies were purchased from EMD Millipore, Inc (Billerica, MA). Phycoerythrin-prominin 1 and FITC-CD45 antibodies were purchased from Miltenyi Biotec, Inc and BD Pharmingen Inc, respectively. For cell treatments, recombinant murine IL10 and TGFβ were obtained from R&D Systems, Inc (Minneapolis, MN).
Animals and Surgeries
Institutional Review Board approval was obtained from the institutional biosafety committee of Temple University. All animal experiments adhered to the protocols approved by the Institutional Animal Care and Use Committee of Temple University. Eight-to 10-week-old WT (C57BL/6J) and IL10KO (Il10 tm1Cgn ) mice were procured from Jackson Research Laboratory (Bar Harbor, ME). Male transgenic enhanced green fluorescent protein (eGFP)-expressing (C57BL/6-Tg[CAG-EGFP]10sb/J) mice served as a donor source in BM transplantation (BMT) experiments. Before surgery, baseline echocardiography data were collected for all animals. Cardiac hypertrophy and subsequent heart failure were induced by constriction of the transverse aorta with a 27-gauge needle as described previously.
32,36
Isolation of Prominin 1-Positive Cells and Treatments
Prominin 1-positive cells (BM-FPCs) were isolated from BM of both WT and IL10KO mice with the prominin 1 and CD45 magnetic bead double-selection method. BM-FPCs were isolated from BM mononuclear cells with density-gradient centrifugation as described previously. 34 Briefly, BM cells were isolated from both fore and hind limbs. For positive cell separation, monocyte/macrophage-depleted BM cells were incubated with prominin 1 magnetic bead for 25 to 30 minutes. After serial washing steps, the cells were cultured in expansion medium (Iscove modified Dulbecco medium with 20% FBS, 100 µmol/L β-mercaptoethanol, 1% nonessential amino acids, and 1% antibiotic/antimycotic; Mediatech). Ten to 12 days after culture, cells were detached with trypsin (0.05% with EDTA), and CD45-positive progenitor cells were sorted from expanded total prominin 1-positive cells with CD45 magnetic beads. The sorted prominin 1 + CD45 + cells were plated onto 1% gelatin-coated plates in expansion medium until confluency. For in vitro experiments, cells were starved in serum-free medium for 12 hours. BM-FPCs were pretreated with IL10 (20 ng/mL) for 1 hour followed by TGFβ (20 ng/mL) for 6 (protein analysis), 24 (RNA analysis), or 72 (immunostaining) hours.
Bone Marrow Transplantation and Surgery
To elucidate the role of IL10 in BM-FPC homing to the heart, we conducted BMT experiments using eGFP-transgenic mice as BM donors as described previously. 34 For BMT, recipient female IL10KO mice (5 weeks old) were lethally irradiated with a 6.0-Gy dose followed by intravenous injection of 2×10 6 donor BM cells isolated from male donor eGFP + WT mice. At 5 weeks after BMT, recipient IL10KO chimeric mice were subjected to TAC surgery as described previously. 32, 36 At day 5, TAC-induced mobilization of BM-FPCs was determined by fluorescence-activated cell sorter (FACS) analysis of peripheral blood mononuclear cells. On day 28, after final echocardiography, mice were euthanized, and heart was isolated for biochemical analysis.
Tissue Preparation and Flow Cytometry
Flow cytometry analysis of the BM-FPC population was performed on cells isolated from blood and heart as described previously. 34 Blood was collected into EDTA-containing tubes either via tail vein cut (from live mice) or via cardiac rupture (from euthanized mice). Whole blood was stained with fluorochrome-conjugated antibodies (CD45-FITC and prominin 1-phycoerythrin), and erythrocytes were then lysed with a BD FACS lysis solution (BD Biosciences). After blood collection, hearts were perfused with EDTA-supplemented Hank balance salt solution and chopped into small pieces. For single cell preparation, the chopped heart pieces were digested with a mixture of collagenase D and DNase I (both from Roche) in Hank balance salt solution at 37°C for 40 minutes and filtered through 70-μm nylon mesh. Erythrocytes ORIGINAL RESEARCH ARTICLE were lysed with BD Pharm Lyse (BD Biosciences) and counted with trypan blue to discriminate the dead cells. The freshly isolated heart or mononuclear cells from peripheral blood (tail vein) were separated with antibodies against CD45-FITC (BD Pharmingen Inc) and prominin 1-phycoerythrin (Miltenyi Biotec, Inc) and sorted on an LSRII flow cytometer for size and granularity by forward scatter and side scatter. Isotype-matched IgG antibodies were used as negative controls. Quantitative fluorescence analysis was performed with Flow-Jo Software (Tree Star, Inc); 50 000 events were counted per sample.
Cardiac Imaging
Transthoracic 2-dimensional M-mode echocardiography was performed with a Vevo 770 (VisualSonics, Toronto, ON, Canada) equipped with a 30-MHz transducer. Echocardiographic studies were performed before (baseline) and at 28 days after surgery. Percent fractional shortening and percent ejection fraction were calculated as described previously. 34, 37, 38 
Tissue Preparation and Masson Trichrome Staining
Whole hearts were perfused first with sterile cold PBS followed by 10% formalin for 5 to 10 minutes. Atria were removed and ventricles were fixed in 10% phosphate-buffered formalin for 24 hours. Twenty to 25 sections (4 µm each) were prepared from each heart, and Masson trichrome staining and quantification were done with Nikon NIS software.
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Quantitative Real-Time Polymerase Chain Reaction
Gene expression levels of collagen 1α, TGFβ, αSMA, and FSP1 were quantified in the prominin 1 + fibroblasts progenitor cells as described previously. 32 RNA was collected with the Trizol RNA isolation kit. Total RNA was reverse transcribed with iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA), and amplification was performed with a Taqman 7700 (Applied Biosystems, Foster City, CA). Relative mRNA expression of target genes was normalized to the endogenous 18S control gene (Applied Biosystems) and represented as fold change versus respective controls.
miRNA Expression Analysis
Polymerase chain reaction-based miRNA array was performed to measure the levels of fibrosis-associated miRNA in BM-FPCs as per the manufacturer's instructions (RT2 Profiler, SABiosciences). 35 Briefly, total RNA was collected with the Trizol RNA isolation kit (Qiagen). Total RNA was reverse transcribed with provided cDNA Synthesis Kit (Qiagen), and amplification was performed with a StepOnePlus (Applied Biosystems). Relative expression of target miRNAs was normalized to the endogenous U6 control gene (Applied Biosystems) and represented as fold change versus respective controls.
Preparation of Cell Lysates and Western Blotting
FPCs were lysed in radioimmunoprecipitation assay cell lysis buffer (Cell Signaling, Boston, MA) supplemented with protease inhibitor pellets (Amersham Biosciences, Piscataway, NJ). Insoluble debris was removed by centrifugation (25 000g) for 15 minutes at 4°C, and cell lysates were boiled with Laemmli sample buffer (0.5 mol/L Tris-HCl [pH 6.8], 10% SDS, 10% glycerol, 4% β-merceptoethenol, and 0.05% bromophenol blue). Equal amounts of protein (20 µg) were separated by SDS-PAGE and assessed by Western blotting in indicated proteins. GAPDH was used as a loading control.
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Immunofluorescent Staining
Immunofluorescent staining for prominin 1, collagen 1α, FSP1, and α-SMA was performed on tissue sections or on FPCs plated onto chamber slides coated with 1% gelatin. BM-FPCs were grown to ≈80% confluence (5-7 days) in culture expansion media. The medium was changed to serum-free Iscove modified Dulbecco medium for treatment. Before immunostaining, cells were washed with PBS, fixed in 4% paraformaldehyde for 15 minutes, and permeabilized for 10 minutes with 0.2% Triton 100. BM-FPCs were incubated for 1 hour (22°C) with blocking solution (3% BSA, 10% horse serum, and 0.2% Triton X-100) to block nonspecific binding. Cells were then incubated at 37°C for 1 hour with primary antibodies and 45 minutes with the appropriate secondary antibody conjugated to Alexa 488 or Alexa 594 (Invitrogen). DAPI was used to counterstain the nuclei. Cells were covered with mounting medium (Invitrogen), overlaid with a coverslip, and examined under a fluorescence microscope. For tissue sections, all the steps are identical after the deparaffinization steps.
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Statistical Analysis
Results are expressed as the mean±SEM computed from separate experiments. Comparisons of continuous variables between treatment groups were performed with the nonparametric Kruskal-Wallis test for ≥3 groups (level of significance was determined by the Dunn nonparametric test) and the exact Wilcoxon rank-sum test for 2 groups because of the small group sizes to guard against possibly nonnormally distributed data. When data were collected over time on the same set of animals such as percent fractional shortening and percent ejection fraction, they were analyzed with a mixed-effects model to take into account the correlation among repeated measures and the potential nonconstant variability over time across different groups. Multiple comparisons among treatment groups were performed with 1-way or 2-way repeated ANOVA, and levels of significance were determined with the Tukey-Kramer multiple-comparison post hoc test. The statistical analysis was performed with GraphPad Prism 6.0h Software (GraphPad Inc, San Diego, CA). Values of P<0.05 were considered to be statistically significant. P values and numbers (group size) are reported in the figure legends.
RESULTS
Augmented TAC-Induced Mobilization and Homing of BM-FPCs in IL10KO Mice
To investigate whether IL10 regulates TAC-induced mobilization and homing of BM-FPCs to the heart, we evaluated BM-FPC mobilization and homing in WT and IL10KO mice 5 days after TAC surgery by FACS. BM-FPCs were identified as the subpopulation of lineage negative hematopoietic cells (CD45 + ) expressing prominin 1 as described previously. 15, 21 As shown in Figure 1A , TAC significantly induced BM-FPC mobilization from BM to the peripheral blood in both WT and IL10KO mice; however, the TAC-induced circulating BM-FPC number was augmented in IL10KO mice. Furthermore, to assess the homing of BM-FPCs to the heart, FACS was performed in the enzyme-digested WT and IL10KO mice hearts cells from WT and IL10KO mice 5 days after TAC surgery. An increased number of BM-FPCs were detected in the WT hearts after TAC compared with hearts from sham-operated WT mice. Pressure overload-induced recruitment of BM-FPCs into the heart was further augmented in IL10KO mice ( Figure 1B ).
IL10 Inhibits TGFβ-Induced Transdifferentiation of BM-FPCs to Myofibroblasts
BM-FPCs were isolated from BM of WT mice. To induce BM-FPC transdifferentiation, cells were treated with TGFβ (20 ng/mL) in the presence or absence of IL10 (20 ng/mL). At the end of the treatment, cells were washed with cold PBS, fixed in 4% paraformaldehyde (15 minutes), and stained with αSMA (myofibroblast marker) and prominin 1 (Figure 2A-2D) . TGFβ treatment enhanced αSMA expression in BM-FPCs (Figure 2C) . Furthermore, TGFβ-treated cells also showed myofibroblast-like spindle shape morphology. TGFβ-induced αSMA expression and morphological change were markedly inhibited by IL10 treatment ( Figure 2D and 2E), suggesting that IL10 inhibits TGFβ-induced BM-FPC transdifferentiation to myofibroblasts.
TGFβ-Induced Fibrotic Gene Expression Was Inhibited by IL10
To define the myofibroblast phenotype in TGFβ-treated cells, we measured the expression of fibroblast-associated genes (TGFβ, Figure 3A ; collagen 1α, Figure 3B ; FSP-1, Figure 3C ; and αSMA, Figure 3D ) by quantitative real-time polymerase chain reaction. TGFβ treatment significantly enhanced fibrosis-associated gene expression in BM-FPCs ( Figure 3A through 3D) . TGFβ-induced fibrosis-associated gene expression was reduced by IL10 treatment ( Figure 3A through 3D) . These data further substantiate that IL10 inhibits BM-FPC transdifferentiation to myofibroblasts.
IL10 Inhibits TGFβ Signaling in BM-FPCs
To understand the effect of TGFβ treatment on myofibroblast-related protein expression and signaling, we measured the αSMA protein levels in cell lysates isolated from FPCs after IL10 and TGFβ treatment. TGFβ significantly increased αSMA protein levels in BM-FPCs; conversely, this increase was inhibited by IL10 treatment ( Figure 3E and 3F ). This result further confirms that IL10 inhibits BM-FPC transdifferentiation. Furthermore, to determine the contribution of TGFβ downstream signaling molecules on BM-FPC transdifferentiation, Western blot for pSmad2/3 was performed in whole-cell lysates from BM-FPCs after TGFβ or IL10 treatment. TGFβ strikingly increased Smad2/3 phosphorylation, and corroborating our other results, Smad2/3 phosphorylation was markedly reduced by IL10 treatment (Figure 3E and 3G) . 
BM-FPCs Transdifferentiate Into Myofibroblasts in Pressure-Overloaded Myocardium
To evaluate whether FPCs homed into the heart, 5 days after TAC, left ventricular sections from IL10KO chimeric (eGFP-WT BM recipient) mice were examined by immunofluorescence microscopy for GFP and prominin 1 expression. Our data demonstrate that TAC induced recruitment of WT BM progenitor cells to the heart (Figure 5A and 5B). GFP-prominin 1 double-positive cells (yellow) were noticeably detectable in chimeric mouse hearts 5 days after TAC. These results confirm that pressure overload significantly enhances recruitment of BM-FPCs to the heart ( Figure 5B ). Furthermore, to study the contribution of these cells to cardiac fibrosis, 28 days after TAC, left ventricular sections from chimeric IL10KO mice were examined for coexpression of GFP and αSMA (myofibroblast marker). As a result of reduced BM-FPC mobilization in sham mice, very few GFP-positive cells were seen. TAC induction resulted in a notable increase in double-positive cells and those coexpressing GFP and αSMA ( Figure 5C and 5D). The presence of double-positive cells suggests that BM progenitor cells in the failing hearts transdifferentiated to myofibroblasts (yellow). To further validate the myofibroblast phenotype, left ventricular sections were examined for the myofibroblast marker procollagen 1α (red) coexpressed with GFP with similar results ( Figure  I in the online-only Data Supplement).
WT BM Reconstitution in IL10KO Mice Partially Reduced Cardiac Fibrosis and Improved Cardiac Function in the Pressure-Overloaded Myocardium
Because WT BMT noticeably reduced the mobilization of fibroblast progenitors, we next assessed whether reduced FPC homing affects cardiac fibrosis in the chimeric IL10KO mice after TAC. Masson trichrome staining was performed to see the collagen deposition in the heart sections. As expected, IL10KO mice showed exaggerated fibrosis compared with WT mice after surgery ( Figure 6A through 6D). WT BMT in IL10KO mice significantly attenuated TAC-induced exaggerated fibrosis ( Figure 6C  and 6D) . Furthermore, cardiac function was measured on baseline and 15 and 28 days after TAC by echocardiography. Cardiac function was greatly impaired in IL10KO mice compared with WT mice after surgery. WT BMT in IL10KO chimeric mice significantly improved heart function ( Figure 6E and 6F).
TGFβ Augments Fibrosis-Associated miRNA Expression in IL10KO-Derived FPCs
To understand the underlying mechanisms of TGFβ-induced FPC transdifferentiation, we performed a se- ries of in vitro experiments in isolated FPCs. Because miRNAs control a wide range of physiological/pathological processes, including profibrotic signaling, 25, 26 we assessed the role of miRNAs on BM-FPC transdifferentiation and whether IL10 regulates its expression. Fibrosis-associated miRNA expression was analyzed in WT and IL10KO BM-FPCs at the basal level with a polymerase chain reaction-based miRNA microarray platform (Qiagen). miRNA array data showed that several miRNAs were differentially expressed in IL10KO BMFPCs compared with WT BM-FPCs ( Figure 7A ). Among these, miRNA-21, -145, and -208a were highly upregulated in IL10KO BM-FPCs compared with WT BM-FPCs. 
miR-21 Overexpression Attenuates the Effect of IL10 on TGFβ-Induced BM-FPC Transdifferentiation
Previous studies have suggested a significant role of miRNA-21 in TAC-induced cardiac fibrosis. 30 To determine whether IL10 negatively regulates miR-21 expression and thus inhibits BM-FPC transdifferentiation, WT BM-FPCs were transfected with miR-21 mimic and respective control scrambled RNA. miRNA-21 mimic transfection significantly increased the miRNA-21 expression level in BM-FPCs ( Figure 8A ). Furthermore, fibrosis-associated gene expression was also measured in miRNA-21 mimic-treated cells after IL10 or TGFβ treatment. TGFβ-induced fibrotic gene (TGFβ, Col1α, Col3α, and FSP-1) expression was augmented in miRNA-21 mimic-treated cells ( Figure 8B through 8E) . Moreover, the inhibitory effect of IL10 on TGFβ-induced fibrotic genes expression was almost completely ablated by miRNA-21 overexpression (Figure 8B through 8E) . These ORIGINAL RESEARCH ARTICLE results demonstrate that the inhibitory effect of IL10 on TGFβ-induced BM-FPC transdifferentiation is miRNA-21 dependent.
DISCUSSION
Fibrosis is an evolutionarily conserved process that serves to facilitate host defense and wound healing. Deregulated fibrosis, however, is invariably associated with loss of organ function. For instance, cardiac fibrosis is correlated with elevated mortality in dilated cardiomyopathy, which is the most common cardiomyopathy globally and directly correlates with sudden cardiac death, heart failure, and arrhythmia. 12 Despite significant progress in identifying molecular mechanisms and factors that contribute to hypertrophy over the past decades, the mechanistic basis of cardiac fibrosis is still not well understood. This study demonstrates that in addition to resident cardiac fibroblasts, BM-derived fibroblasts significantly contribute to the progression of pathological cardiac fibrosis and remodeling and that pleotropic anti-inflammatory cytokine IL10 inhibits the recruitment and transdifferentiation of BM-FPCs into the pressure-overloaded myocardium. Furthermore, we show that IL10 noticeably inhibits TGFβ-Smad2/3 signaling in activated BM-FPCs. We reported the suppression of TGFb-Smad2/3 signaling-mediated miRNA-21 maturation as a novel mechanism by which IL10 might potentially inhibit BM-FPC-mediated cardiac fibrosis in the pressure-overloaded myocardium.
Structural fibroblasts are considered one of the most abundant cell types in the adult myocardium that perform structural function and provide the source of continued renewal of matrix proteins. 4 Although cardiac fibroblasts are highly active during organ development, cardiac fibroblasts of the adult heart are quiescent and maintain only a low-level turnover of extracellular matrix. 5 In response to tissue injury (including mechanical, ischemic, or inflammatory), fibroblasts are activated, become myofibroblasts, and are involved in active matrix deposition and tissue fibrosis. Recent evidence suggests that the overall number of myofibroblasts in the injured myocardium is rapidly increased as a result of the proliferation of existing fibroblasts and transdifferentiation from BM hematopoietic cells, endothelial cells, or epicardial cells. 16 Recent literature advocates that a subpopulation of heart-infiltrating BM-derived CD45 + cells, expressing prominin 1 and other stem cell markers (c-Kit and Sca-1), contributes to cardiac fibrosis under the influence of TGFβ. 15, 20, 21 These cells are common progenitors for fibroblasts and macrophages. The inflammatory stimulus (macrophage colony-stimulating factor) induced their differentiation to macrophages; however, fibrotic stimuli (TGFβ) induced their differentiation to myofibroblasts. In sex-mismatched BMT experiments, Zeisberg et al 18 have shown that almost 21% of myofibroblasts are derived from the BM in fibrotic lesions after pressure overload. In agreement with these data, we also found that pressure overload enhances mobilization and homing of CD45/prominin 1-positive cells to the heart. The mobilization of cells from this source was further augmented in IL10KO mice. Our result suggests that IL10 negatively regulates the homing of BM-FPCs to the heart. This notion was further confirmed in our BMT experiments in which transplantation of WT BM in IL10KO chimeric mice partially reduced BM-FPC mobilization after TAC. Acute inflammatory stimulus during myocardial infarction leads to release of hematopoietic and mesenchymal stem cells from BM and to their recruitment to the heart. 40, 41 The primary role of BM cells (including monocytes/macrophages, endothelial cells, and other mesenchymal cell) trafficking to the heart is cardiac repair, but a prolonged inflammatory state leads to adverse remodeling and cardiac cell death. 42 Therefore, a tight regulation of inflammation is indeed important for adequate cardiac repair during inflammation-associated heart disease. We and others have previously shown that IL10 attenuated both myocardial infarction and pressure overloadinduced inflammation in mouse heart and improved cardiac function. 32, 33, 37 Because inflammatory stimuli play an important role in the BM microenvironment and biology of BM cells, the reduced mobilization of FPCs in IL10KO chimeric mice in this study could be due to changes in the BM microenvironment (caused by WT BM cell transplantation). Hearts from chimeric mice were perfused with PBS, fixed in formalin, and embedded in paraffin. A, Five days after TAC surgery, heart sections were immunostained with green fluorescent protein (GFP) and prominin 1 antibodies. B, The number of BM-derived prominin 1-positive cells was increased in hearts after TAC surgery. C, To assess BM-derived myofibroblasts in heart, 28 days after TAC, heart sections were immunostained with GFP (for BM origin) and α-smooth muscle actin (α-SMA; myofibroblast marker). D, The increased number of double-positive BM-derived myofibroblasts (yellow) was seen in interleukin-10 knockout (IL10KO) chimeric mouse hearts. Green indicates GFP; red, prominin 1 (A) or α-SMA (C); and blue, DAPI. The original magnification was ×400. The quantitative data are presented on log10 scale value. IL10KO chimeric mice are IL10KO knockout mice with wild-type mice BM transplantation (n=6).***P<001 vs chimeric mice sham group.
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In the past years, regeneration of ischemic myocardial tissue has been attempted with BM-derived stem cells and wide variety of stem cells As an alternative to direct intramyocardial injection, mobilization of BMderived stem cells with growth factors such as the hematopoietic cytokine granulocyte colony-stimulating factor or even IL10 has been successful. 34, 43 Migration of circulating mobilized BM-derived stem cells from the bloodstream into the damaged tissue is suggested to play a key role in tissue regeneration. In fact, we have recently shown that homing of endothelial progenitor cells is important for adequate cardiac repair after myocardial infarction. The compromised BM environment in IL10KO mice leads to impaired release of endothelial progenitor cells from BM. 34 In contrast to BM endothelial progenitor cells, IL10KO mice BM facilitated the homing of fibroblasts progenitor cells to the heart after TAC in this study. Our data indicate that IL10 has differential effects on the release of subsets of BM cells. The differential effect of IL10 on release of BM subsets could be the long-term chronic heart failure model used in present study.
It is well established that TGFβ enhances the transition from acute inflammatory phase to chronic fibrotic phase during pathological heart disease. 15, 44 We have previously shown that IL10KO mice showed exaggerated TGFβ gene expression within 7 days in pressureoverloaded myocardium, which ultimately led to exaggerated cardiac fibrosis. 32 In the present study, we found that the BM-FPCs are recruited to the heart mostly after 5 to 7 days after surgery ( Figure 5A and 5B). Kania et al 15, 20 have recently shown that blockade of TGFβ signaling with TGFβ-neutralizing antibody inhibits transdifferentiation of BM prominin 1-positive cells to myofibroblasts. Thus, the augmented fibrotic response of pressure overload in IL10KO mice could be due to enhanced recruitment and transdifferentiation (in the presence of TGFβ) of BM-FPCs. The TGFβ-induced BM-FPC transdifferentiation was significantly reduced by recombinant IL10 treatment. These results suggest that in addition to reducing mobilization of BM-FPCs, IL10 inhibits transdifferentiation of BM-FPC to myofibroblasts and associated fibrotic signaling. TGFβ drives the fibrotic process by binding to the heterodimeric membrane receptor, which results in phosphorylation and subsequent nuclear translocation of the SMAD family of transcription factors. Thus, inhibition of the specific cellular receptors, kinases, and other mediators involved in activation of the TGFβ pathway may provide effective therapeutic targets for treating cardiac fibrosis. 45, 46 Impedance of cellular differentiation and Smad2/3 phosphorylation by IL10 suggests that IL10 holds pertinent therapeutic potential for treatment of heart failure by its strong inhibitory role in BM-FPCmediated fibrosis in pressure-overloaded myocardium. To this point, our data show that reduced recruitment of BM-FPCs in IL10KO chimeric mice partially inhibited myocardial fibrosis and improved heart function after TAC compared with that observed in IL10KO mice.
The pathogenesis of the fibrogenic cardiac phenotype is still being elucidated, but recent studies have demonstrated that in addition to canonical TGFβ fibrotic signaling molecules, several miRNAs contribute to myocardial fibrosis in the pressure-overloaded myocardium. 25, 26, 47 In vivo silencing of miR-21 suppresses extracellular signal-regulated kinase-mitogen-activated protein kinase fibrotic signaling and prevents cardiac dysfunction in a mouse pressure overload-induced disease model. miR-21 regulates fibroblast survival and growth factor secretion, which ultimately control the extent of interstitial fibrosis and cardiac hypertrophy. 30 To understand the underlying mechanisms by which IL10 alters TGFβ-induced BM-FPCs transdifferentiation, we assayed miRNA expression using a commercially available fibrotic miRNAs array platform in WT or IL10KO BM-FPCs at the basal level. The expression of most profibrotic miRNAs was increased in IL10KO BM-FPC compared with WT BM-FPC. Among the levels of all miRNAs tested, miRNA-21 was highly upregulated in IL10KO FPCs. Previous studies have shown that biogenesis of miRNA-21 is regulated by TGFβ-Smad signaling in smooth muscle cells. 28, 29 The biogenesis of miRNA-21 is tightly regulated by DROSHA. Davis et al 28 , and Blahna and Hata 29 have shown that TGFβ-Smad signaling is important for DROSHA-mediated miRNA21maturation. Here, our data suggest that IL10 inhibits TGFβ-induced Smad2/3 activation. We also present here that IL10 treatment significantly inhibits TGFβ-induced miRNA-21 expression. We further validated these data by overexpressing miRNA-21 using a mimic in WT BM-FPC before IL10 and TGFβ treatment. miRNA-21 mimic treatment attenuated the inhibitory effect of IL10 on fibrosis-associated gene expression in BM-FPCs. Thus, we speculated that the IL10-mediated reduction in TGFβ-Smad2/3 signaling in this study may regulate DROSHA protein levels and ultimately control miRNA-21 levels in activated BM-FPCs ( Figure 8F ). This possibility warrants thorough investigation in future studies.
CONCLUSIONS
We demonstrated here for the first time that BMFPCs play an important role during pressure overload- ORIGINAL RESEARCH ARTICLE induced cardiac fibrosis. IL10 negatively regulates the TAC-induced BM-FPC recruitment to the heart. We also show that in addition to reduced BM-FPC homing, IL10 changes the microenvironment of the heart and thus inhibits BM-FPC activation. At the molecular level, IL10 via TGFβ-Smad signaling mechanism might modulate the miR-21 maturation process and therefore inhibit pressure overload-induced cardiac fibrosis. Because BM-FPCs are involved in cardiac fibrosis only during pathological stress, selective inhibition of their homing to the heart and of fibrotic signaling with IL10 might inhibit transition of physiological hypertrophy to heart failure and may be a potential therapeutic strategy to treat or prevent the development of heart disease. A model showing the possible mechanism of IL10-mediated inhibition of TAC-induced cardiac fibrosis is shown in Figure 8F .
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